Catalent, Inc. (NYSE:CTLT – Get Rating) – Equities research analysts at Zacks Research dropped their Q3 2023 earnings estimates for shares of Catalent in a report issued on Tuesday, May 9th. Zacks Research analyst D. Dey now forecasts that the company will post earnings of ($0.32) per share for the quarter, down from their previous estimate of $0.71. The consensus estimate for Catalent’s current full-year earnings is $2.60 per share. Zacks Research also issued estimates for Catalent’s Q4 2023 earnings at $0.76 EPS, FY2023 earnings at $1.37 EPS, Q2 2024 earnings at $0.41 EPS, Q3 2024 earnings at $0.40 EPS, Q4 2024 earnings at $1.12 EPS, FY2024 earnings at $2.13 EPS, Q1 2025 earnings at $0.42 EPS, Q3 2025 earnings at $0.74 EPS and FY2025 earnings at $3.18 EPS.
Catalent (NYSE:CTLT – Get Rating) last released its quarterly earnings results on Tuesday, February 7th. The company reported $0.62 EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.02). Catalent had a return on equity of 11.40% and a net margin of 8.62%. The company had revenue of $1.15 billion for the quarter, compared to the consensus estimate of $1.12 billion.
A number of other analysts also recently commented on CTLT. Bank of America downgraded shares of Catalent from a “neutral” rating to an “underperform” rating and set a $28.00 target price on the stock. in a report on Monday, May 8th. Barclays cut their price target on shares of Catalent from $70.00 to $40.00 in a report on Monday, April 17th. Robert W. Baird downgraded shares of Catalent from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $82.00 to $53.00 in a research report on Monday, April 17th. StockNews.com upgraded shares of Catalent to a “sell” rating in a research note on Saturday, April 15th. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Catalent from $72.00 to $55.00 in a research note on Tuesday. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $77.40.
Catalent Stock Down 3.9 %
NYSE CTLT opened at $32.86 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.91 and a quick ratio of 1.38. The company’s 50 day simple moving average is $56.68 and its 200 day simple moving average is $54.22. Catalent has a 12 month low of $32.21 and a 12 month high of $115.33. The company has a market capitalization of $5.92 billion, a P/E ratio of 14.54, a PEG ratio of 2.38 and a beta of 1.17.
Insiders Place Their Bets
In other Catalent news, SVP Mario Gargiulo sold 678 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $33,805.08. Following the sale, the senior vice president now owns 5,676 shares of the company’s stock, valued at approximately $283,005.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Manja Boerman sold 1,446 shares of the stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $72,097.56. Following the sale, the insider now directly owns 14,414 shares in the company, valued at approximately $718,682.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mario Gargiulo sold 678 shares of the stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $33,805.08. Following the completion of the sale, the senior vice president now owns 5,676 shares in the company, valued at $283,005.36. The disclosure for this sale can be found here. Insiders own 0.58% of the company’s stock.
Institutional Trading of Catalent
Several hedge funds have recently bought and sold shares of CTLT. Cetera Advisor Networks LLC lifted its position in Catalent by 7.1% during the first quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock worth $217,000 after purchasing an additional 130 shares during the period. Mackay Shields LLC increased its position in Catalent by 0.6% during the 1st quarter. Mackay Shields LLC now owns 25,749 shares of the company’s stock valued at $2,856,000 after purchasing an additional 149 shares during the period. Texas Permanent School Fund grew its position in shares of Catalent by 0.8% during the 4th quarter. Texas Permanent School Fund now owns 25,569 shares of the company’s stock worth $1,151,000 after buying an additional 212 shares during the period. Global Strategic Investment Solutions LLC grew its position in shares of Catalent by 3.4% during the 4th quarter. Global Strategic Investment Solutions LLC now owns 6,937 shares of the company’s stock worth $312,000 after buying an additional 229 shares during the period. Finally, Czech National Bank lifted its holdings in shares of Catalent by 1.1% in the 4th quarter. Czech National Bank now owns 21,065 shares of the company’s stock worth $948,000 after purchasing an additional 238 shares in the last quarter. 99.38% of the stock is currently owned by institutional investors and hedge funds.
About Catalent
(Get Rating)
Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
Featured Stories
Receive News & Ratings for Catalent Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Catalent and related companies with MarketBeat.com’s FREE daily email newsletter.